Kristine Wellman - Chemours Gen VP
CC Stock | MXN 385.07 0.00 0.00% |
Insider
Kristine Wellman is Gen VP of The Chemours
Phone | 302 773 1000 |
Web | https://www.chemours.com |
Kristine Wellman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Kristine Wellman against Chemours stock is an integral part of due diligence when investing in Chemours. Kristine Wellman insider activity provides valuable insight into whether Chemours is net buyers or sellers over its current business cycle. Note, Chemours insiders must abide by specific rules, including filing SEC forms every time they buy or sell Chemours'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Kristine Wellman 19 hours ago Acquisition by Kristine Wellman of 20671 shares of Chemours at 27.5 subject to Rule 16b-3 |
Chemours Management Efficiency
The company has return on total asset (ROA) of 0.0653 % which means that it generated a profit of $0.0653 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.5281 %, meaning that it generated $0.5281 on every $100 dollars invested by stockholders. Chemours' management efficiency ratios could be used to measure how well Chemours manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | INSIDER Age | ||
David Bem | PPG Industries | 53 | |
Bhaskar Ramachandran | PPG Industries | N/A | |
Javier Santos | Vitro SAB de | N/A | |
Malesia Dunn | PPG Industries | N/A | |
Roberto Sanchez | ALPEK SAB de | N/A | |
Jos Pea | ALPEK SAB de | N/A | |
Alfonso Tamez | Vitro SAB de | N/A | |
Francisco Egloff | ALPEK SAB de | N/A | |
Jose Larrea | ALPEK SAB de | N/A | |
Jose Contreras | Vitro SAB de | N/A | |
Andreas Rutishauser | ALPEK SAB de | N/A | |
Alejandro Mjica | Vitro SAB de | 69 | |
Jaime Kuper | ALPEK SAB de | N/A | |
Shlomo Frymerman | Vitro SAB de | N/A | |
Armando Cantu | ALPEK SAB de | N/A | |
David Garza | ALPEK SAB de | N/A | |
Alejandro Fernandez | ALPEK SAB de | N/A | |
Ricardo Maiz | Vitro SAB de | N/A | |
Ral Hinojosa | Vitro SAB de | 74 | |
Peg Curry | PPG Industries | N/A | |
Adrin Meouchi | Vitro SAB de | N/A |
Management Performance
Return On Equity | 0.53 | |||
Return On Asset | 0.0653 |
Chemours Leadership Team
Elected by the shareholders, the Chemours' board of directors comprises two types of representatives: Chemours inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Chemours. The board's role is to monitor Chemours' management team and ensure that shareholders' interests are well served. Chemours' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Chemours' outside directors are responsible for providing unbiased perspectives on the board's policies.
Mark Newman, CFO, Senior Vice President | ||
Edwin Sparks, President - Chemical Solutions | ||
Jonathan Lock, Sr Officer | ||
Kurt Bonner, Ma Relations | ||
Kristine Wellman, Gen VP | ||
Alisha Bellezza, Director of Investor Relations | ||
Sameer Ralhan, CFO, Senior Vice President Treasurer | ||
Susan Kelliher, Senior Vice President – Human Resources and Health Services | ||
Camela Wisel, Chief VP | ||
Alvenia Scarborough, Sr Officer |
Chemours Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Chemours a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.53 | |||
Return On Asset | 0.0653 | |||
Profit Margin | 0.09 % | |||
Operating Margin | 0.12 % | |||
Current Valuation | 146.34 B | |||
Shares Outstanding | 148.5 M | |||
Shares Owned By Insiders | 1.09 % | |||
Shares Owned By Institutions | 77.77 % | |||
Price To Earning | 82.94 X | |||
Price To Book | 3.61 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Chemours Stock Analysis
When running Chemours' price analysis, check to measure Chemours' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chemours is operating at the current time. Most of Chemours' value examination focuses on studying past and present price action to predict the probability of Chemours' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chemours' price. Additionally, you may evaluate how the addition of Chemours to your portfolios can decrease your overall portfolio volatility.